Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Korro Bio $70 million private placement
The PIPE consists of common stock
TScan Therapeutics $150 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
EyeCare Partners new refinancing transaction
We advised the superpriority, first-lien and second-lien administrative agent and the fronting bank on the transaction
Intra-Cellular Therapies $500 million stock offering
The shares are listed on the Nasdaq Global Select Market
Nurix Therapeutics $175 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
Biodesix $55 million follow-on offering
The common stock is listed on the Nasdaq Global Market
Adagene $100 million at-the-market offering
We advised Adagene on the offering
Stoke Therapeutics $125 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Select Market
AnHeart Therapeutics acquisition by Nuvation Bio
We are advising AnHeart Therapeutics on the acquisition
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO